pemrametostat (GSK3326595) / Ipsen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pemrametostat (GSK3326595) / Ipsen
METEOR-1, NCT02783300: An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

Hourglass Oct 2019 - Dec 2019 : Proof-of-concept data in solid tumors and NHL
Completed
1
288
Europe, Canada, US
GSK3326595, Pembrolizumab
GlaxoSmithKline
Neoplasms
08/23
08/23

Download Options